(Q67697065)

English

High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: A preliminary report

scientific article published on 01 June 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: A preliminary report (English)

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

1 reference

based on heuristic

inferred from title

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

author name string

P. B. Panici

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

S. Greggi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

G. Scambia

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

G. Ragusa

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

G. Baiocchi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

F. Battaglia

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

F. Coronetta

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

S. Mancuso

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1714417

6 November 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1714417

6 November 2022

publication date

1 June 1991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

full work available at URL

https://api.elsevier.com/content/article/PII:0090825891903102?httpAccept=text/xml

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

https://api.elsevier.com/content/article/PII:0090825891903102?httpAccept=text/plain

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

41

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

212-216

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumor

1

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Results of a phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri

2

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma

3

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer

4

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

The integration of chemotherapy into the management of locally advanced cervical cancer: A pilot study

5

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival

7

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Squamous cervical cancer at stage IB and II: a ten years experience, analysis of 231 cases

8

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Phase III study on the treatment of women with cervical cancer, stage IIB, IIIB, and IVA (confined to the pelvis and/or periaortic nodes), with radiotherapy alone versus radiotherapy plus immunotherapy with intravenous Corynebacterium parvum: a Gyne

9

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Analysis of results of radiation therapy for Stage II carcinoma of the cervix

10

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Carcinoma of the cervix, stage III. Results of radiation therapy

11

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

High-dose-rate afterloading brachytherapy in carcinoma of the uterine cervix

12

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

High-Dose Cisplatin in Hypertonic Saline

15

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

High-dose platinum for the treatment of refractory ovarian cancer

17

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary

18

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug

19

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer

20

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Primary chemotherapy and postoperative adjuvant chemotherapy in the treatment of squamous cell carcinoma of the uterine cervix

25

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

V factor (tumor volume) and T factor (FIGO classification) in the assessment of cervix cancer prognosis: the risk of lymph node spread.

26

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Cisplatin, vincristine, methotrexate and bleomycin (POMB) as initial or palliative chemotherapy for carcinoma of the cervix

27

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix

28

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

The importance of dose and dose intensity in lung cancer chemotherapy

29

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.

31

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

The role of pharmacokinetics in (combination) chemotherapy

32

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Dose-Dependent Metabolism, Therapeutic Effect, and Toxicity of Anticancer Drugs in Man

33

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy

34

1 reference

10.1016/0090-8258(91)90310-2

https://api.crossref.org/works/10.1016/0090-8258(91)90310-2

6 November 2022

Identifiers

10.1016/0090-8258(91)90310-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1714417%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67697065&oldid=1765796102"